hepat
c
viru
hcv
hepatotrop
pathogen
caus
liver
diseas
includ
fibrosi
cirrhosi
steatosi
insulin
resist
iron
overload
hepatocellular
carcinoma
estim
million
peopl
chronic
infect
hcv
major
caus
liver
diseas
worldwid
repres
global
healthcar
concern
unfortun
prevent
vaccin
protect
hcv
infect
avail
standard
care
therapi
pegyl
plu
ribavirin
costli
poorli
toler
associ
signific
side
effect
effect
fraction
chronic
infect
individu
therefor
pathogen
discuss
within
chapter
need
develop
hcv
antiinfect
healthcar
imper
although
sever
small
molecul
target
hcv
replic
clinic
pipelin
emerg
viral
escap
mutant
indic
combin
drug
target
multipl
aspect
infect
like
requir
success
treat
major
patient
thu
unit
aim
facilit
discoveri
hcv
antivir
describ
method
test
evalu
promis
antivir
compound
vitro
abil
screen
hcv
antivir
inhibit
aspect
infect
made
possibl
develop
first
robust
vitro
hcv
infect
model
lindenbach
et
al
wakita
et
al
zhong
et
al
recapitul
entir
viral
life
cycl
allow
hcv
propag
cell
cultur
unit
focus
procedur
compound
screen
basic
protocol
describ
screen
compound
activ
microtit
plate
format
use
nondivid
synchron
hepatoma
cell
allow
reproduc
hcv
infect
vitro
use
low
multipl
infect
approach
basic
protocol
describ
simpl
hcv
proteas
assay
use
assess
hcv
infect
determin
compound
efficaci
stock
infecti
hcv
requir
basic
screen
protocol
support
protocol
detail
prepar
necessari
hcv
stock
also
provid
support
protocol
explain
gener
infecti
hcv
hcv
rna
support
protocol
describ
amplif
origin
hcv
stock
support
protocol
list
method
assess
infect
titer
hcv
stock
produc
togeth
protocol
encompass
sever
new
approach
compound
screen
hcv
antivir
drug
discoveri
caution
hcv
biosafeti
level
pathogen
follow
appropri
guidelin
regul
use
handl
pathogen
microorgan
see
unit
pertin
resourc
appendix
inform
note
solut
equip
come
contact
live
cell
must
steril
asept
techniqu
use
accordingli
note
cultur
incub
perform
humidifi
incub
unless
otherwis
specifi
cell
japan
health
scienc
research
resourc
bank
cat
http
wwwjhsforjp
cell
mainten
medium
see
recip
cell
mainten
medium
vv
dimethyl
sulfoxid
dmso
tissu
cultur
grade
compound
libraryhcvcc
stock
titer
see
support
protocol
fret
lysi
buffer
see
recip
prechil
larger
tissu
cultur
clear
black
microtit
biocoat
tissu
cultur
plate
bd
bioscienc
microtit
platespl
seal
addit
reagent
equip
grow
mammalian
cell
phelan
sampl
plate
basic
protocol
fret
peptid
substrat
anaspec
resuspend
distribut
aliquot
upon
receipt
fret
assay
buffer
anaspec
dithiothreitol
dtt
appendix
fluoresc
micropl
reader
excit
emiss
filtersshak
platformcentrifug
microtit
plate
carrier
hcv
encod
plasmid
kato
et
al
xbai
restrict
endonucleas
compat
bufferbuff
phenol
ph
appendix
distil
phenolchloroformisoamyl
alcohol
see
appendix
sodium
acet
ph
see
appendix
vv
vv
vitro
rna
transcript
reagent
eg
ambion
megascript
rna
transcript
reaction
buffer
also
see
recip
lindenbach
et
al
datp
dgtp
dctp
dutp
stock
solut
also
see
appendix
rna
dnase
also
see
appendix
gel
electrophoresi
apparatu
reagent
includ
agaroset
buffer
appendix
wv
ethidium
bromid
appendix
sampl
load
buffer
contain
bromphenol
blue
appendix
dna
size
cell
japan
health
scienc
research
resourc
bank
cat
http
wwwjhsforjp
cell
mainten
medium
see
recip
dulbecco
phosphat
buffer
salin
dpb
without
calcium
magnesium
see
recip
appendix
prepar
omit
trypsin
tissu
cultur
grade
mm
edta
hbss
see
appendix
hbss
dmem
andor
avail
invitrogen
prechil
tissu
cultur
conic
centrifug
tubesinvert
light
microscoperefriger
centrifug
electropor
cellulos
acet
filter
steril
addit
reagent
equip
determin
dna
rna
concentr
gallagh
desjardin
rna
purif
purif
kit
total
rna
purif
kit
ribozol
plu
rna
purif
kit
amresco
inc
http
wwwamrescoinccom
lithium
chlorid
precipit
kaper
chromatographi
phenol
chloroform
extract
isopropanol
precipit
chomczynski
sacchi
kingston
et
al
determin
hcvcc
infect
titer
support
protocol
cell
japan
health
scienc
research
resourc
bank
cat
http
wwwjhsforjp
cell
mainten
medium
see
recip
gener
hcvcc
support
protocol
dulbecco
phosphat
buffer
salin
dpb
without
calcium
magnesium
see
recip
appendix
prepar
omit
trypsin
tissu
cultur
grade
mm
edta
hbss
see
appendix
hbss
tissu
cultur
conic
centrifug
tube
bd
falcon
refriger
cellulos
acet
filter
steril
cell
japan
health
scienc
research
resourc
bank
cat
cell
mainten
medium
see
recip
hcvcc
test
sampl
see
protocol
cell
mainten
medium
wv
methylcellulos
see
recip
pfa
fixat
buffer
see
recip
dulbecco
phosphat
buffer
salin
dpb
without
calcium
magnesium
see
recip
appendix
prepar
omit
dpb
without
contain
hydrogen
peroxid
prepar
immedi
use
block
buffer
see
recip
primari
antibodi
ab
eg
human
antibodi
law
et
al
mous
antibodi
lindenbach
et
al
mous
core
affin
bioreag
bind
buffer
see
recip
appropri
secondari
antibodi
ab
dakocytom
envis
label
antibodi
primari
ab
rais
mous
goat
antibodi
pierc
primari
ab
rais
human
aec
peroxidas
substrat
solut
bd
bioscienc
vv
glycerol
tissu
cultur
microtit
platesinvert
light
microscop
ml
dulbecco
salin
dpb
without
calcium
magnesium
see
recip
appendix
prepar
omit
g
bovin
serum
albumin
fraction
ml
vv
triton
ml
total
volum
dpb
without
filter
steril
use
cellulos
acet
filterstor
year
final
composit
triton
ml
dulbecco
salin
dpb
without
calcium
magnesium
see
recip
appendix
prepar
omit
g
bovin
serum
albumin
fraction
ml
vv
triton
ml
fetal
bovin
serum
fb
final
min
bring
ml
total
volum
dpb
without
filter
steril
use
cellulos
acet
filterstor
year
final
composit
triton
fb
vv
triton
mm
ph
appendix
mm
mm
edtastor
year
ml
dulbecco
minim
essenti
medium
dmem
ml
mm
ml
nonessenti
amino
ml
hepe
ml
fetal
bovin
serum
fb
final
min
ml
penstrep
uml
penicillin
g
sodium
streptomycin
sulfat
store
month
methylcellulos
stock
solut
add
g
methylcellulos
methocel
mc
fluka
cat
ml
water
steril
bottl
contain
stir
bar
stir
methylcellulos
partial
goe
solut
hr
heat
methylcellulos
dissolv
cold
solut
steril
autoclav
allow
solut
return
room
temperatur
methylcellulos
solidifi
shake
vigor
break
clump
transfer
overnight
possibl
stir
methylcellulos
gradual
go
solut
methylcellulos
overlay
add
part
methylcellulos
stock
solut
part
cell
mainten
medium
mix
well
store
dark
g
paraformaldehyd
pfa
ml
dulbecco
salin
dpb
without
calcium
magnesium
see
recip
appendix
prepar
omit
adjust
ph
n
naoh
pfa
go
solut
ph
aid
dissolut
heat
solut
fume
hood
let
solut
rise
bring
ml
total
volum
dpb
without
filter
steril
wrap
aluminum
foil
store
year
mm
ph
appendix
mm
sodium
mm
magnesium
chloridealiquot
store
year
hepat
c
viru
hcv
hepatotrop
envelop
rna
viru
primari
caus
agent
liver
diseas
worldwid
current
hcv
affect
million
individu
global
caus
signific
liver
diseas
includ
cirrhosi
hepatocellular
carcinoma
hcc
chronic
infect
individu
alter
seeff
fact
unit
state
hcc
account
hcc
case
liver
transplant
perform
annual
hcv
classifi
famili
flavivirida
base
conserv
viral
rna
polymeras
genom
organ
lindenbach
rice
kb
rna
genom
flank
highli
structur
untransl
region
encod
singl
open
read
frame
translat
via
viral
intern
ribosom
entri
site
viral
polyprotein
viral
polyprotein
cleav
structur
nonstructur
ns
protein
host
viral
proteas
ns
viral
protein
assembl
cellular
membran
endoplasm
reticulum
mediat
format
viral
rna
replic
complex
also
known
membran
web
neg
strand
rna
synthesi
occur
gosert
et
al
rna
provid
templat
amplif
genom
rna
subsequ
encapsid
viral
nucleocapsid
protein
ie
core
direct
cellular
lipoprotein
secretori
pathway
progeni
virion
matur
becom
lipid
prior
exit
cell
lindenbach
rice
sinc
discoveri
effect
treatment
option
hcv
interferon
treatment
combin
ribavirin
glue
et
al
unfortun
therapi
wide
spectrum
toxic
side
effect
effect
subset
patient
number
hcv
patient
requir
treatment
expect
significantli
increas
next
decad
william
obviou
immedi
need
new
effect
hcv
antivir
result
ht
assay
util
recent
develop
infecti
hcv
cell
cultur
system
lindenbach
et
al
wakita
et
al
zhong
et
al
mean
identifi
new
compound
target
step
hcv
life
cycl
need
unit
describ
uniqu
hcv
ht
fluoresc
reson
energi
transfer
fret
assay
antivir
compound
screen
yu
et
al
combin
use
infecti
hcvcc
hepatoma
cell
cultur
sainz
chisari
choi
et
al
sensit
readout
endogen
proteas
assay
offer
sever
distinct
advantag
convent
hcv
antivir
compound
screen
assay
first
tradit
viral
ht
assay
typic
aim
achiev
synchron
round
viral
replic
use
high
multipl
infect
moi
approach
result
bias
select
inhibitor
target
viral
entri
replic
compound
inhibit
later
viral
infect
process
matur
egress
subsequ
spread
avoid
predisposit
identifi
inhibitor
aspect
viral
life
cycl
hcv
ht
assay
describ
herein
base
infect
multipl
round
hcv
infect
spread
viru
throughout
cultur
occur
inhibitor
target
step
viral
life
cycl
success
identifi
secondli
accommod
long
infect
hcv
ht
assay
make
use
nondivid
synchron
hepatoma
cell
cultur
allow
highli
reproduc
robust
hcvcc
infect
extend
period
time
virtual
elimin
cell
variabl
often
plagu
ht
strategi
addit
cultur
easili
maintain
inher
toler
common
compound
librari
diluent
dimethylsulfoxid
dmso
averag
research
also
advantag
describ
hcv
fret
assay
perform
standard
infecti
hcv
clone
ie
special
report
need
engin
viral
genom
make
use
sensit
commerci
avail
intern
quench
peptid
substrat
cell
cultur
cell
cultur
use
cell
least
usag
cell
within
defin
cell
passag
window
recommend
addit
imper
cell
mycoplasma
free
greater
viabl
use
hcv
infect
affect
variabl
cultur
cell
dmso
induc
cell
growth
arrest
involv
addit
consider
first
method
proven
success
numer
distinct
cell
line
recommend
cell
line
test
individu
ensur
cell
behav
expect
eg
cell
growth
cessat
gene
express
enhanc
occur
approxim
day
post
dmso
treatment
one
potenti
problem
dmso
treatment
excess
dmso
result
cell
death
cytotox
prepar
cell
mainten
medium
vv
dmso
accur
measur
volum
ensur
final
dmso
concentr
use
dmso
sigma
recommend
anoth
potenti
problem
overgrowth
cell
presenc
dmso
happen
cell
mainten
medium
dmso
initi
ad
cultur
late
cell
alreadi
confluent
rather
confluent
judgement
regard
add
medium
subject
determin
empir
begin
experi
cultur
lastli
incub
period
medium
must
chang
everi
day
cell
incub
presenc
dmso
extrem
metabol
activ
thu
util
nutrient
rate
significantli
faster
activ
divid
counterpart
medium
ph
quickli
becom
acid
nutrient
rapidli
exhaust
particularli
day
dmso
treatment
medium
chang
everi
day
therefor
necessari
hcv
infect
ensur
reproduc
throughout
singl
librari
screen
effort
hcvcc
stock
suffici
complet
entir
screen
produc
detail
infect
kinet
establish
prior
screen
subsequ
viru
storag
handl
techniqu
also
standard
compound
screen
unit
describ
approach
accommod
unstabl
compound
must
kept
frozen
minimum
freezethaw
cycl
howev
handl
differ
compound
librari
determin
accord
stabil
properti
compound
test
eg
may
possibl
use
microtit
plate
predilut
drug
suffici
medium
medium
chang
store
infect
perform
screen
standard
posit
neg
control
must
includ
individu
screen
plate
intern
control
result
compar
plate
posit
control
could
known
potent
hcv
inhibitor
ifn
neg
control
includ
diluent
treatment
hcv
fret
assay
simpl
assay
measur
hcv
infect
function
proteas
activ
system
like
ht
assay
howev
critic
care
consid
paramet
lysi
reagent
substrat
activ
statist
valid
assay
data
interpret
lysi
buffer
complet
lysi
cell
need
proper
quantif
proteas
activ
standard
grow
monolay
effici
lyse
tradit
lysi
buffer
includ
provid
manufactur
substrat
anaspec
lysi
cultur
requir
stringent
condit
due
tightli
pack
morpholog
individu
lysi
buffer
empir
test
determin
fret
lysi
buffer
describ
unit
see
reagent
solut
allow
suffici
cell
cultur
lysi
without
reduc
proteas
activ
yu
et
al
addit
recommend
screen
plate
frozen
fret
analysi
cell
undergo
one
cycl
fret
lysi
buffer
substrat
fret
peptid
substrat
anaspec
chosen
high
sensit
howev
fret
peptid
substrat
contain
appropri
hcv
cleavag
site
would
suitabl
long
final
ratio
accept
particular
import
develop
assay
typic
lower
ratio
commonli
ht
assay
zhang
et
al
thu
altern
substrat
util
advis
optim
ratio
test
multipl
lysi
buffer
paramet
appropri
panel
posit
neg
control
prior
perform
compound
screen
campaign
import
fluoresc
tag
peptid
substrat
proper
storag
handl
fluoresc
tag
peptid
substrat
light
temperatur
sensit
care
taken
reduc
exposur
substrat
light
avoid
repeat
cycl
avoid
issu
control
substrat
variabl
recommend
feasibl
obtain
bulk
quantiti
particular
peptid
substrat
lot
immedi
aliquot
ice
individu
tube
kept
storag
fret
peptid
substrat
anaspec
suffici
test
entir
microtit
sampl
plate
aliquot
volum
adjust
base
individu
compound
screen
need
statist
valid
hcv
fret
assay
critic
ht
reproduc
consist
assay
perform
factor
valu
measur
qualiti
assay
assess
dynam
rang
well
variat
within
assay
measur
distanc
standard
deviat
posit
signal
neg
nois
control
valu
also
assess
variabl
noiseerror
associ
assay
ht
consid
accur
valu
greater
necessari
follow
procedur
outlin
unit
hcv
fret
describ
routin
exhibit
factor
greater
yu
et
al
howev
empir
determin
userlaboratori
data
interpret
success
compound
screen
assay
lie
abil
assay
distinguish
hit
thu
import
calcul
assay
hit
ratio
determin
appropri
hit
window
identifi
candid
compound
describ
zhang
et
al
biolog
perspect
advis
follow
compound
reproduc
inhibit
hcv
relat
hit
zone
hit
zone
identifi
unmanag
number
hit
stringent
hit
window
eg
establish
likewis
compound
identifi
use
hit
zone
hit
window
increas
eg
accept
test
compound
potenti
inhibitor
hcvcc
rna
qualiti
abil
effici
produc
infecti
hcvcc
transfect
hcv
rna
depend
presenc
suffici
quantiti
hcv
rna
genom
express
vector
contain
promot
suitabl
vitro
rna
transcript
kb
rna
genom
optim
may
necessari
optim
synthesi
larg
hcv
rna
transcript
even
use
commerci
avail
transcript
kit
accord
manufactur
recommend
highli
recommend
rna
visual
gel
electrophoresi
assess
rna
qualiti
describ
brown
et
al
presenc
predomin
smear
rna
differ
size
rather
predomin
singl
band
slight
smear
incomplet
product
indic
incomplet
transcript
degrad
neg
impact
intracellular
hcv
rna
replic
follow
transfect
addit
rnase
inhibitor
optim
transcript
reaction
incub
period
help
ensur
rna
stock
contain
high
percent
intact
hcv
rna
genom
rna
longer
genom
length
observ
may
indic
complet
linear
templat
dna
thu
get
continu
rna
synthesi
around
intact
plasmid
resolv
either
redigest
templat
incorpor
step
linear
templat
dna
separ
agaros
gel
purif
final
contamin
protein
residu
phenol
chloroform
ethanol
may
reduc
transfect
effici
spectrophotometr
analysi
vitro
transcrib
rna
recommend
confirm
rna
puriti
purif
includ
option
proteinas
k
treatment
step
perform
necessari
obtain
better
rna
puriti
transfect
origin
report
describ
gener
hcvcc
vitro
transcrib
rna
util
electropor
transfect
cell
lindenbach
et
al
wakita
et
al
zhong
et
al
differ
cell
line
may
respond
optim
slightli
differ
electropor
condit
paramet
describ
repres
reason
start
point
optim
addit
choic
transfect
method
theoret
limit
electropor
methodolog
cation
transfect
use
lipofectamin
invitrogen
also
use
compar
efficaci
zhong
et
al
thu
transfect
protocol
suitabl
long
intact
rna
deliv
effect
target
cell
effici
least
case
advis
first
ensur
least
determin
parallel
transfect
protocol
effect
use
plasmid
vector
encod
report
gene
gfp
hcv
replic
failur
produc
detect
level
infecti
hcvcc
may
also
due
inadequ
intracellular
replic
transfect
hcv
rna
although
major
cell
permiss
hcvcc
infect
support
robust
hcv
replicon
rna
replic
sainz
et
al
specif
laboratori
cell
line
may
support
initi
hcv
rna
replic
effici
assess
intracellular
hcv
rna
replic
follow
transfect
quantit
hcv
rna
quantit
polymeras
chain
reaction
perform
describ
sainz
et
al
likewis
hcv
protein
level
indic
effici
rna
replic
determin
immunostain
describ
support
protocol
cell
major
import
gener
hcvcc
stock
state
cell
propag
optim
cellular
condit
hcvcc
grow
titer
ffuml
howev
mycoplasma
contamin
chang
state
host
cell
neg
impact
hcv
rna
replic
de
novo
viru
product
pietschmann
et
al
windisch
et
al
nelson
tang
sainz
chisari
thu
critic
use
cell
maintain
healthi
growth
state
allow
becom
time
transfect
infect
point
thereaft
moreov
passag
cell
permiss
hcvcc
infect
fluctuat
corcoran
et
al
unpub
observ
henc
particularli
ensur
reproduc
throughout
hcv
screen
effort
recommend
cell
passag
monitor
cell
cultur
limit
number
passag
ie
split
time
cell
discard
equival
frozen
aliquot
thaw
continu
use
obvious
requir
cell
use
initi
expand
larg
number
parallel
aliquot
frozen
futur
use
lastli
mycoplasma
contamin
avoid
cell
line
treat
determin
mycoplasma
posit
see
appendix
suboptim
viral
titer
although
hcv
consid
noncytolyt
viru
hcvcc
infect
cell
result
detect
cytopath
effect
cpe
character
slow
cell
growth
appear
round
sometim
float
cell
degre
cpe
observ
vari
among
differ
cell
line
sainz
et
al
onset
cpe
usual
coincid
maxim
titer
product
harvest
viru
initi
onset
cpe
recommend
titer
achiev
method
describ
unit
suboptim
specif
downstream
purpos
higher
titer
obtain
concentr
viral
stock
use
centrifug
concentr
amicon
centrifug
filter
unit
millipor
harvest
medium
viru
concentr
least
without
loss
infect
cell
mutat
mention
support
protocol
propag
rna
virus
mutat
incorpor
viral
genom
everi
time
replic
due
intrins
error
rate
lack
proofread
function
viral
rna
polymeras
henc
continu
passag
cell
cultur
select
specif
adapt
mutant
occur
zhong
et
al
mutat
confer
advantag
viral
growth
cell
cultur
randomli
occur
time
infect
signific
shift
viru
popul
whole
usual
requir
sever
week
continu
viru
select
occur
thu
hcvcc
propag
method
describ
support
protocol
typic
result
emergenceselect
specif
mutat
bulk
sequenc
viru
present
medium
collect
day
post
transfect
day
post
subsequ
infect
indic
detect
select
cell
cultur
mutat
past
viru
stock
prepar
howev
bulk
sequenc
empir
confirm
conclus
way
whether
adapt
mutat
select
within
specif
viru
stock
hcv
infect
titer
assay
describ
support
protocol
base
standard
titer
protocol
success
util
numer
virus
condit
howev
paramet
note
abnorm
andor
difficult
count
hcv
foci
although
noncytolyt
hcv
form
discret
foci
monolay
ideal
hr
cell
fix
stain
hcv
protein
posit
foci
consist
group
cell
howev
sometim
individu
foci
readili
distinguish
due
unexpect
differ
size
shape
foci
although
foci
size
vari
depend
specif
cell
line
use
titer
sainz
et
al
often
case
simpl
adjust
made
optim
foci
format
first
help
includ
simpl
overlay
minim
secondari
spread
give
rise
satellit
foci
thu
addit
wv
methylcellulos
recommend
ensur
format
countabl
discret
hcv
foci
addit
foci
larg
hr
cell
fix
stain
earlier
eg
hr
contrast
foci
small
reliabl
count
may
result
cell
time
infect
suboptim
media
condit
use
cell
contamin
mycoplasma
incub
level
exceed
inconsist
suboptim
stain
immunostain
methodolog
issu
antibodi
specif
cell
permeabl
background
may
aris
protocol
describ
herein
use
antibodi
list
provid
tabl
design
ensur
maximum
stain
visual
hcv
foci
inconsist
suboptim
stain
encount
reagent
first
check
altern
standard
chang
antibodi
dilut
incub
period
incub
temperatur
test
lastli
addit
permeabil
step
consist
singl
wash
methanol
vv
incorpor
support
protocol
step
hcvcc
fret
assay
describ
herein
use
effect
procedur
test
efficaci
potenti
hcv
antivir
aspect
viral
life
cycl
use
cell
cultur
provid
uniqu
cell
cultur
environ
test
efficaci
test
compound
hcv
impart
advantag
virtual
elimin
variabl
routin
encount
compound
screen
assay
use
activ
divid
cell
cultur
earli
day
post
incub
dmso
cell
enter
growth
arrest
soon
thereaft
form
tightli
pack
monolay
binucl
cell
display
typic
cytolog
featur
primari
hepatocyt
previous
describ
yu
et
al
cell
support
robust
hcvcc
infect
therefor
follow
day
infect
hcv
proteas
activ
measur
fret
fluoresc
yield
maxim
rfu
valu
untreat
ratio
sampl
treat
compound
inhibit
hcv
step
viral
life
cycl
eg
entri
uncoat
translat
replic
assembl
matur
egress
yield
rfu
valu
significantli
untreat
control
well
exampl
potent
inhibitor
hcv
infect
reduc
fret
rfu
valu
compar
untreat
control
sampl
uncommon
see
variat
rfu
valu
experi
experi
work
differ
substrat
lot
see
critic
paramet
substrat
howev
inhibit
appropri
calcul
rel
proper
control
percent
reduct
compar
experi
experi
gener
hcvcc
cell
either
transfect
hcv
rna
support
protocol
infect
cell
hcvcc
support
protocol
yield
titer
ffuml
howev
due
variat
inher
hcvcc
infect
observ
due
part
cell
linesclon
util
time
post
transfect
post
infect
yield
maxim
titer
vari
nonetheless
follow
protocol
describ
within
unit
maxim
titer
cell
achiev
day
post
transfect
day
post
infect
hcvcc
gener
hcv
infect
titer
assay
support
protocol
use
determin
viral
titer
express
ffuml
assay
yield
discret
hcv
foci
consist
hcv
cell
fret
assay
describ
unit
basic
protocol
take
sever
week
complet
howev
assay
divid
manag
stop
point
along
way
afford
effici
execut
entir
assay
start
finish
compound
librari
screen
endeavor
proper
plan
prior
begin
assay
advis
ensur
need
reagentscompound
avail
appropri
dilut
correct
time
mandatori
step
prepar
cell
infect
occur
appropri
interv
throughout
assay
end
design
strateg
plan
advanc
initi
assay
prevent
unanticip
error
delay
fret
assay
divid
two
basic
protocol
requir
total
day
basic
protocol
hr
basic
protocol
complet
therefor
procedur
complet
either
tandem
altern
exampl
step
end
basic
protocol
repres
stop
point
sampl
plate
store
indefinit
thu
author
advis
basic
protocol
perform
suffici
number
sampl
plate
fret
analysi
accumul
ensur
consist
fret
result
assay
plate
procedur
perform
togeth
cours
day
rather
stagger
across
sever
week
addit
advis
prepar
cell
cultur
plate
stagger
manag
number
plate
handl
one
time
sinc
cell
must
incub
week
ie
day
presenc
dmso
batch
plate
seed
weekli
thu
reduc
number
plate
treat
infect
one
time
aforement
suggest
howev
depend
number
compound
test
liquid
handl
equip
avail
addit
fret
assay
describ
basic
protocol
support
protocol
detail
procedur
gener
hcvcc
determin
infect
titer
gener
hcvcc
accomplish
transfect
cell
hcv
rna
support
protocol
infect
cell
hcvcc
support
protocol
requir
day
day
respect
hcvcc
gener
infect
titer
analysi
perform
support
protocol
within
day
time
vari
depend
method
detect
hrp
versu
immunofluoresc
number
well
count
